Editas Medicine Inc. (NASDAQ:EDIT) Director Kevin Bitterman sold 21,480 shares of the business’s stock in a transaction dated Wednesday, November 23rd. The stock was sold at an average price of $15.71, for a total transaction of $337,450.80. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Kevin Bitterman also recently made the following trade(s):

  • On Tuesday, November 15th, Kevin Bitterman sold 88,900 shares of Editas Medicine stock. The stock was sold at an average price of $16.96, for a total transaction of $1,507,744.00.

Editas Medicine Inc. (NASDAQ:EDIT) traded down 1.70% on Monday, reaching $15.03. 274,006 shares of the company traded hands. The stock’s 50 day moving average price is $14.51 and its 200 day moving average price is $21.70. Editas Medicine Inc. has a one year low of $12.43 and a one year high of $43.99. The company’s market capitalization is $535.58 million.

Editas Medicine (NASDAQ:EDIT) last posted its earnings results on Monday, November 7th. The company reported ($0.59) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.64) by $0.05. Editas Medicine had a negative net margin of 1,184.46% and a negative return on equity of 59.22%. The firm earned $1 million during the quarter, compared to analysts’ expectations of $1 million. The firm’s quarterly revenue was up 49.3% on a year-over-year basis. On average, equities research analysts predict that Editas Medicine Inc. will post ($2.49) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2016/11/28/editas-medicine-inc-edit-director-sells-337450-80-in-stock.html.

Several equities research analysts have recently commented on EDIT shares. Jefferies Group reissued a “buy” rating on shares of Editas Medicine in a research report on Monday, August 22nd. Zacks Investment Research upgraded shares of Editas Medicine from a “sell” rating to a “hold” rating in a report on Tuesday, September 20th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Editas Medicine presently has a consensus rating of “Buy” and a consensus target price of $30.75.

Several large investors have recently bought and sold shares of the company. FMR LLC raised its position in shares of Editas Medicine by 0.9% in the second quarter. FMR LLC now owns 5,452,061 shares of the company’s stock valued at $133,030,000 after buying an additional 50,031 shares during the last quarter. Flagship Ventures Fund IV General Partner LLC acquired a new position in shares of Editas Medicine during the second quarter valued at about $120,910,000. Price T Rowe Associates Inc. MD raised its position in shares of Editas Medicine by 32.5% in the third quarter. Price T Rowe Associates Inc. MD now owns 1,874,396 shares of the company’s stock valued at $25,267,000 after buying an additional 460,280 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of Editas Medicine by 159.0% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 170,739 shares of the company’s stock valued at $2,302,000 after buying an additional 104,808 shares during the last quarter. Finally, BlackRock Fund Advisors raised its position in shares of Editas Medicine by 2.8% in the second quarter. BlackRock Fund Advisors now owns 163,385 shares of the company’s stock valued at $3,987,000 after buying an additional 4,466 shares during the last quarter. 60.89% of the stock is owned by hedge funds and other institutional investors.

About Editas Medicine

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

5 Day Chart for NASDAQ:EDIT

Receive News & Stock Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related stocks with our FREE daily email newsletter.